Outcomes of Resected Lung Cancer Diagnosed Through Screening and Incidental Pulmonary Nodule Programs in a Mississippi Delta Cohort.

Early lung cancer detection programs improve surgical resection rates and survival but may skew toward more indolent cancers. Hypothesizing that differences in stage-stratified survival indicate differences in biological aggressiveness and possible length-time and overdiagnosis bias, we assessed a cohort who had curative-intent resection, categorized by diagnostic pathways: screening, incidental pulmonary nodule program, and non-program based. Survival was analyzed using Kaplan-Meier plots, log-rank tests, and Cox regression, comparing aggregate and stage-stratified survival across cohorts with Tukey's method for multiple testing. Of 1588 patients, 111 patients (7%), 357 patients (22.5%), and 1120 patients (70.5%) were diagnosed through screening, pulmonary nodule, and non-program-based pathways; 0% versus 9% versus 6% were older than 80 years ( Neither length-time nor overdiagnosis bias was evident in NSCLC diagnosed through screening or incidental pulmonary nodule programs.

Informations de copyright

© 2024 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.

Déclaration de conflit d'intérêts

Dr. Matthew P. Smeltzer is a paid research consultant for the Association of Community Cancer Centers. Dr. Raymond U. Osarogiagbon holds patents for surgical specimen collection kit and stocks in Pfizer, Gilead Sciences, and Eli Lilly; is a paid research consultant for the American Cancer Society, the Association of Community Cancer Centers, Genentech/Roche, Biodesix, Lungevity Foundation, National Cancer Institute, Tryptych Healthcare Partners, and AstraZeneca; and is founder of Oncobox Device, Inc. The remaining authors declare no conflict of interest.